Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice
The DOI matches its Crossref record.
Abstract
There is a growing body of evidence that the formation and accumulation of advanced glycation end products (AGE) have been known to progress under diabetic conditions, thereby being involved in diabetic vascular complications. Further, we, along with others, have recently found AGE could disturb insulin actions in cultured adipocytes and skeletal muscles. However, the pathological role of AGE in insulin resistance in vivo is not fully understood. Therefore, in this study, we examined whether pyridoxamine, an inhibitor of AGE formation could ameliorate insulin resistance in KK-A(y) mice, a model animal of obese, type 2 diabetes. Fasting blood glucose, serum levels of insulin and AGE in KK-A(y) mice were elevated as the mice got older (from 5 weeks old to 15 weeks old). Serum levels of AGE were positively correlated with insulin (R(2)=0.3956, P=0.002) in KK-A(y) mice. Administration of pyridoxamine dose-dependently decreased fasting insulin levels and improved insulin sensitivity in KK-A(y) mice of 10 weeks old, although it did not affect fasting blood glucose levels. Our present study suggests the involvement of AGE in insulin resistance in KK-A(y) mice. Inhibition of AGE formation may be a novel therapeutic target for improving insulin resistance in diabetes with obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
Nowotny, K., Jung, T., Höhn, A., Weber, D., & Grune, T. (2015) · Biomolecules · doi:10.3390/biom5010194 · Cited by 1,095
“The agents pyridoxamine or TM2002 inhibit the formation of AGEs and were shown to improve insulin resistance in rodents which already suffered from diabetes [91] or in which insulin resistance was induced by the administration of methylglyoxal [92].”
BackgroundAdvanced glycation endproducts in food and their effects on health
Poulsen, M. W., Hedegaard, R. V., Andersen, J. M., de Courten, B., Bügel, S., Nielsen, J., Skibsted, L. H., & Dragsted, L. O. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.06.052 · Cited by 751
Oxenkrug, G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8497-4 · Cited by 254
Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity
Gaens, K. H., Stehouwer, C. D., & Schalkwijk, C. G. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835aea13 · Cited by 166
Galliera, E., Marazzi, M. G., Gazzaruso, C., Gallotti, P., Coppola, A., Montalcini, T., Pujia, A., & Corsi Romanelli, M. M. (2017) · Immunity & Ageing · doi:10.1186/s12979-017-0097-0 · Cited by 18
Metadata
- Authors
- Unoki-Kubota, H., Yamagishi, S.-I., Takeuchi, M., Bujo, H., & Saito, Y.
- Venue
- Protein & Peptide Letters
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-09-01
- Volume
- 17
- Issue
- 9
- Pages
- 1177-1181
- ISSN
- 0929-8665 (ISSN-L)
- OpenAlex
- W2000478369
- Cited by
- 54
- References
- 0
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice. https://app.cochat.ai/papers/10.2174/092986610791760423
- The paper
- Unoki-Kubota, H., Yamagishi, S.-I., Takeuchi, M., Bujo, H., & Saito, Y. (2010). Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice. Protein & Peptide Letters. https://doi.org/10.2174/092986610791760423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.